Clinical Trial Results

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PHASE3INTERVENTIONAL Gilbert, Arizona +4 more

RECRUITING

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

PHASE2INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

PHASE3INTERVENTIONAL Anchorage, Alaska +4 more

RECRUITING

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

PHASE2INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

PHASE3INTERVENTIONAL Tucson, Arizona +4 more

RECRUITING

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

PHASE2INTERVENTIONAL Long Beach, California +4 more

RECRUITING

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

PHASE1INTERVENTIONAL Tucson, Arizona +4 more

RECRUITING

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

PHASE3INTERVENTIONAL Hot Springs, Arkansas +4 more

RECRUITING

CtDNA Based MRD Testing for NAC Monitoring in TNBC

N/AOBSERVATIONAL Tucson, Arizona +4 more

RECRUITING

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

PHASE3INTERVENTIONAL Springdale, Arkansas +4 more

RECRUITING

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

PHASE3INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING